Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders
Phobia, Social, Panic Disorder, Agoraphobia
About this trial
This is an interventional treatment trial for Phobia, Social focused on measuring Generalized social phobia, Comorbid panic disorder with agoraphobia, Comorbid obsessive compulsive disorder, Comorbid generalized anxiety disorder, Comorbid major depressive disorder/Dysthymia
Eligibility Criteria
Inclusion Criteria: Outpatient with primary Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) GSP plus at least one of the following comorbid DSM-IV anxiety disorders: panic disorder with agoraphobia obsessive compulsive disorder major depressive disorder generalized anxiety disorder Score on LSAS > 50 Score on MADRS < 25 Exclusion Criteria: Any other primary AXIS-I diagnosis Criteria for alcohol/substance abuse/dependence History (Hx) of bipolar disorder, schizophrenia or other psychotic disorder A comorbid Axis II cluster A personality disorder Current increased risk of concomitant suicide Allergy/previous intolerance during an adequate trial (50mg/day for minimum of 4 weeks) of sertraline Participation in any clinical trial 30 days prior to entering the study Unable to tolerate being free of/shows signs of withdrawal from benzodiazepines for 4 weeks Hx of seizures Thyroid problems
Sites / Locations
- MacAnxiety Research Centre
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
1
2
Sertraline
Placebo